Epcoritamab for Korean patients with lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tracks how well epcoritamab, an injection for certain types of lymphoma (DLBCL and follicular lymphoma), works in Korean adults. It also checks for side effects during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult in Korea with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) that has come back or not improved after treatment.
- Your doctor has decided to treat you with epcoritamab as part of your regular care, or you have already started this treatment.
- You agree to participate and sign a consent form.
- You are not currently in another clinical trial (observational studies are okay).
- You do not have any medical condition that makes epcoritamab unsafe for you, as listed on the approved label.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.